{"organizations": [], "uuid": "adcb69d1ae052cd330a9c55f932997c80328c1b6", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-contravir-pharmaceuticals-reaches/brief-contravir-pharmaceuticals-reaches-agreement-with-the-fda-idUSFWN1Q20NX", "country": "US", "domain_rank": 408, "title": "BRIEF-ContraVir Pharmaceuticals Reaches Agreement With The FDA", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-12T13:32:00.000+02:00", "replies_count": 0, "uuid": "adcb69d1ae052cd330a9c55f932997c80328c1b6"}, "author": "", "url": "https://www.reuters.com/article/brief-contravir-pharmaceuticals-reaches/brief-contravir-pharmaceuticals-reaches-agreement-with-the-fda-idUSFWN1Q20NX", "ord_in_thread": 0, "title": "BRIEF-ContraVir Pharmaceuticals Reaches Agreement With The FDA", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "contravir pharmaceuticals inc", "sentiment": "none"}, {"name": "fda reuters staff", "sentiment": "none"}, {"name": "nda", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "February 12, 2018 / 11:33 AM / in 9 minutes BRIEF-ContraVir Pharmaceuticals Reaches Agreement With The FDA Reuters Staff 1 Min Read \nFeb 12 (Reuters) - Contravir Pharmaceuticals Inc: \n* CONTRAVIR PHARMACEUTICALS REACHES AGREEMENT WITH THE FDA ON THE NDA PACKAGE FOR TXLâ„¢ LEVERAGING THE 505(B)(2) REGULATORY PATHWAY \n* CONTRAVIR PHARMACEUTICALS - FDA ALLOWS CO TO USE 505(B)(2) REGULATORY PATHWAY TO STREAMLINE DEVELOPMENT & REGISTRATION OF TXL FOR TREATING CHRONIC HEPATITIS B Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-12T13:32:00.000+02:00", "crawled": "2018-02-12T13:53:00.001+02:00", "highlightTitle": ""}